4.7 Review

Prevention and Treatment of Acute Myeloid Leukemia Relapse after Hematopoietic Stem Cell Transplantation: The State of the Art and Future Perspectives

Journal

JOURNAL OF CLINICAL MEDICINE
Volume 11, Issue 1, Pages -

Publisher

MDPI
DOI: 10.3390/jcm11010253

Keywords

allogeneic bone marrow transplantation; relapse; acute leukemia

Ask authors/readers for more resources

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative option for high-risk acute myeloid leukemia (AML). Advances in pre-transplant induction therapies, supportive care, donor selection, and conditioning regimens have expanded the patient population eligible for HSCT. The introduction of novel agents and targeted therapies have enriched the treatment landscape for AML relapse after HSCT, while close monitoring of minimal-residual disease (MRD) and preemptive strategies have become essential in post-transplant care.
Allogeneic hematopoietic stem cell transplantation (HSCT) for high-risk acute myeloid leukemia (AML) represents the only curative option. Progress has been made in the last two decades in the pre-transplant induction therapies, supportive care, selection of donors and conditioning regimens that allowed to extend the HSCT to a larger number of patients, including those aged over 65 years and/or lacking an HLA-identical donor. Furthermore, improvements in the prophylaxis of the graft-versus-host disease and of infection have dramatically reduced transplant-related mortality. The relapse of AML remains the major reason for transplant failure affecting almost 40-50% of the patients. From 10 to 15 years ago to date, treatment options for AML relapsing after HSCT were limited to conventional cytotoxic chemotherapy and donor leukocyte infusions (DLI). Nowadays, novel agents and targeted therapies have enriched the therapeutic landscape. Moreover, very recently, the therapeutic landscape has been enriched by manipulated cellular products (CAR-T, CAR-CIK, CAR-NK). In light of these new perspectives, careful monitoring of minimal-residual disease (MRD) and prompt application of pre-emptive strategies in the post-transplant setting have become imperative. Herein, we review the current state of the art on monitoring, prevention and treatment of relapse of AML after HSCT with particular attention on novel agents and future directions.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available